Scalper1 News
Global Blood Therapeutics (GBT) shrugged off the recent slump in biotech stocks and screamed up 130% as of late afternoon on its first day of trading Wednesday, after pricing its 6-million-share IPO at 20, above the expected range. The initial public offering raised $120 million. Global Blood is developing treatments for blood disorders, particularly sickle-cell disease (SCD), a genetic condition that causes anemia. Its lead candidate entered Scalper1 News
Scalper1 News